Therapy News and Research

RSS

FDA approves LUMIGAN eye drops for intraocular pressure reduction in open-angle glaucoma patients

Allergan, Inc. today announced the United States Food and Drug Administration (FDA) has approved LUMIGAN (bimatoprost ophthalmic solution) 0.01% as a first-line therapy indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

2 Sep 2010

TriMark predicts regenerative medicine products will exceed $3 billion in 2010

TriMark Publications, LLC a global leader in the biotechnology, healthcare and life sciences publishing, cites in its newly published Regenerative Medicine Markets report that the global market for regenerative medicine products will exceed $3 billion in 2010 and is expected to reach $4.5 billion by 2014.

2 Sep 2010

PDL BioPharma reports revenue guidance of $86 million for 2010 third quarter

PDL BioPharma, Inc. today announced revenue guidance for the third quarter ended September 30, 2010 of approximately $86 million, as compared with actual results of $71.4 million for the third quarter of 2009, a 20 percent year-over-year increase.

2 Sep 2010

Doctor depression on the rise: Review

According to a review of Australian and international research released by Beyondblue this week, doctors use more prescription drugs and have a higher rate of suicide than the general population. General Practitioner Naomi Harris says doctors are less inclined to seek help for their own mental illness, resulting in some disturbing trends and she is urging doctors to come out for help being a member of an advisory committee formed to deal with the problem.

1 Sep 2010

Event Pulse report reveals impact of new therapies on MS drug market

The study titled Event Pulse Preview: Multiple Sclerosis shows that 84% of neurologists expect to prescribe Gilenia for some MS patients if approved, but prescribing will likely be limited to second- or third-line therapy until concerns about safety and monitoring requirements are resolved.

1 Sep 2010

pSivida announces FDA Priority Review status for Iluvien NDA

pSivida Corp., a leader in the development of sustained release back of the eye drug delivery systems for difficult-to-treat conditions, today announced that its licensee, Alimera Sciences has been notified that the U.S. Food and Drug Administration (FDA) has granted Priority Review status for the New Drug Application (NDA) filed for Iluvien for the treatment diabetic macular edema (DME).

31 Aug 2010

ESC issues revised practice guidelines for management of AF

The European Society of Cardiology today issued revised practice guidelines for the management of atrial fibrillation, including guidance on the role of a novel oral treatment, dabigatran etexilate, for the prevention of stroke and systemic embolism in patients with atrial fibrillation.

31 Aug 2010

Nutritional recommendations for management of sarcopenia published

Nutritional recommendations for the management of sarcopenia -- also described as age-related muscle and functional loss -- were published this past week in the clinical publication, Journal of American Medical Directors Association.

31 Aug 2010

International Symposium to explore Hybrid approach for congenital heart disease

Interventional cardiologists and cardiothoracic surgeons throughout the United States and the world, who treat patients with congenital heart disease, will gather at the Hilton Columbus at Easton Town Center August 31-September 2, 2010 for the International Symposium on the Hybrid Approach to Congenital Heart Disease (ISHAC).

31 Aug 2010

EDIMS licenses First DataBank's National Drug Data File Plus database

First DataBank, a leading provider of drug databases that help drive patient safety, and EDIMS, a leading provider of interoperable emergency department (ED) information management systems, today announced they have licensed First DataBank's National Drug Data File (NDDF) Plus™ database to offer hospitals greater choice in trusted third-party drug database information to use and integrate with EDIMS ED electronic health record (EHR).

31 Aug 2010

Neurobiological markers of depression can help tailor antidepressant treatment to the brain

Depression is actually defined by specific clinical symptoms such as sadness, difficulty to experience pleasure, sleep problems etc., present for at least two weeks, with impairment of psychosocial functioning. These symptoms guide the physician to make a diagnosis and to select antidepressant treatment such as drugs or psychotherapy.

31 Aug 2010

ANTIPAF trial reveals ARBs do not reduce number of AF episodes in paroxysmal AF patients

Atrial fibrillation (AF) is the most common cardiac arrhythmia, affecting about 7 million people in Europe. It is a progressive chronic disease in which episodes become more frequent and long-lasting over time. Conventional anti-arrhythmic therapy aims at halting progression and reducing symptoms, but the use of most anti-arrhythmic drugs is compromised by severe side effects, such as pro-arrhythmia or extra-cardiac organ toxicity.

31 Aug 2010

Data monitoring committee recommends early termination following impressive results of AVERROES study

The data monitoring committee of the AVERROES study, seeing overwhelming evidence of the success of apixaban in the prevention of stroke in patients with atrial fibrillation who are unsuitable for the conventional treatment of warfarin, has recommended early termination of this study. The decision came after repeated review and careful consideration of all efficacy and safety data.

31 Aug 2010

UBC researchers lead development of new 'toolbox of MiniPromoters' for gene research and therapy

University of British Columbia researchers have led the development of a new "toolbox of MiniPromoters" for research and future therapies on brain, spinal cord and eye function.

31 Aug 2010

Study evaluates response to psychotherapeutical interventions in anorexia nervosa

This study demonstrates that the distinction between threshold and subthreshold anorexia nervosa does not seem to be of clinical relevance in terms of response to cognitive-behavioral therapy (CBT). Shape concern rather than demographic or general psychopathological features represents the best predictor of outcome for CBT.

31 Aug 2010

Telmisartan and amlodipine combination therapy helps achieve high BP control/response rates

Data show that treatment with a single-pill combination of telmisartan, an angiotensin receptor blocker, (ARB) and amlodipine, a calcium channel blocker (CCB) results in significant reductions in blood pressure (BP) in patients with severe hypertension.

31 Aug 2010

Phase 3 EINSTEIN-DVT clinical trial data can transform deep vein thrombosis treatment

Johnson & Johnson Pharmaceutical Research & Development, announced today that the investigational, oral anticoagulant rivaroxaban successfully demonstrated non-inferiority compared to the standard of care for the prevention of recurrent venous thromboembolism (VTE) in patients with acute symptomatic deep vein thrombosis (DVT), with a comparable safety profile.

31 Aug 2010

Bioheart's MyoCell adult stem cell therapy shows effective for heart failure patients: Study

Bioheart, Inc., The mission of the Cell Therapy Foundation is to improve public health through the support of effective adult stem cell research and education. The Foundation aims to promote basic and applied knowledge, processes and cell therapies.

31 Aug 2010

Study shows statin therapy not associated with cancer

In the largest and most reliable study of its type, the University of Oxford (UK) and the University of Sydney (Australia) have demonstrated that statin therapy is not a cause of increased cancer rates and deaths. The conclusions of this study will reassure the millions of people worldwide who are taking statins to lower cholesterol levels, and clarifies earlier research that had raised concerns of a causal link.

31 Aug 2010

InSightec's ExAblate Robotic Acoustic Surgery system used for prostate cancer treatment

InSightec Ltd., the global leader in MR guided focused ultrasound technology and the only company to receive FDA approval for its ExAblate(R) system for treating uterine fibroids, announced today that its ExAblate(R) system has been used for the first time for the treatment of prostate cancer patients.

31 Aug 2010

Therapy News and Research

FDA approves LUMIGAN eye drops for intraocular pressure reduction in open-angle glaucoma patients

TriMark predicts regenerative medicine products will exceed $3 billion in 2010

PDL BioPharma reports revenue guidance of $86 million for 2010 third quarter

Doctor depression on the rise: Review

Event Pulse report reveals impact of new therapies on MS drug market

pSivida announces FDA Priority Review status for Iluvien NDA

ESC issues revised practice guidelines for management of AF

Nutritional recommendations for management of sarcopenia published

International Symposium to explore Hybrid approach for congenital heart disease

EDIMS licenses First DataBank's National Drug Data File Plus database

Neurobiological markers of depression can help tailor antidepressant treatment to the brain

ANTIPAF trial reveals ARBs do not reduce number of AF episodes in paroxysmal AF patients

Data monitoring committee recommends early termination following impressive results of AVERROES study

UBC researchers lead development of new 'toolbox of MiniPromoters' for gene research and therapy

Study evaluates response to psychotherapeutical interventions in anorexia nervosa

Telmisartan and amlodipine combination therapy helps achieve high BP control/response rates

Phase 3 EINSTEIN-DVT clinical trial data can transform deep vein thrombosis treatment

Bioheart's MyoCell adult stem cell therapy shows effective for heart failure patients: Study

Study shows statin therapy not associated with cancer

InSightec's ExAblate Robotic Acoustic Surgery system used for prostate cancer treatment

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News